November 3, 2014- Interviewed by Steven E. Greer, MD
Inhaled insulin will make a comeback when Mannkind’s drug, Afrezza, goes on sale in early 2015. It will be marketed by Sanofi.
We interviewed the CEO of Dexcom, Terry Gregg, about how a CGM can play a role in this new therapeutic category. Type-1 diabetes expert, Jay Skyler, MD, also explains the clinic role of CGM with a super-rapid-acting prandial insulin.